Journal of Antimicrobial Chemotherapy (1999) 44, 701-704
© 1999 The British Society for Antimicrobial Chemotherapy
Brief report |
A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose
Department of Medical Microbiology, City Hospital NHS Trust, Birmingham B18 7QH, UK
A single 400 mg oral dose of gatifloxacin was given to each of nine healthy male volunteers and the concentrations of the drug in plasma, cantharidine-induced inflammatory fluid and urine were measured over the following 24 h. The mean peak concentration in plasma of 4.1 mg/L was attained at a mean time of 1.8 h post dose. The mean peak concentration in inflammatory fluid was 3.6 mg/L and was attained at a mean time of 4.2 h post dose. The mean plasma elimination half-life of gatifloxacin was 6.8 h and that in inflammatory fluid was 7.2 h. The mean penetration into the inflammatory fluid was 117%. Recovery of drug from urine during the first 24 h post dose was 65% of that administered. Our data suggest that gatifloxacin dosed at 400 mg od should be adequate to treat systemic infections caused by most bacterial species.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. M. Rubino, E. V. Capparelli, J. S. Bradley, J. L. Blumer, G. L. Kearns, M. Reed, R. F. Jacobs, B. Cirincione, and D. M. Grasela Population Pharmacokinetic Model for Gatifloxacin in Pediatric Patients Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1246 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Noreddin, V. L. Haynes, and G. G. Zhanel Pharmacokinetics and Pharmacodynamics of the New Quinolones Journal of Pharmacy Practice, December 1, 2005; 18(6): 432 - 443. [Abstract] [PDF]
|
|
|
|
|
|
A. Trampuz, G. Laifer, M. Wenk, Z. Rajacic, and W. Zimmerli Pharmacokinetics and Pharmacodynamics of Gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a Granulocyte-Rich Exudate Antimicrob. Agents Chemother., November 1, 2002; 46(11): 3630 - 3633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Andes and W. A. Craig Pharmacodynamics of the New Fluoroquinolone Gatifloxacin in Murine Thigh and Lung Infection Models Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1665 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wise, T. Gee, G. Marshall, and J. M. Andrews Single-Dose Pharmacokinetics and Penetration of BMS 284756 into an Inflammatory Exudate Antimicrob. Agents Chemother., January 1, 2002; 46(1): 242 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ince and D. C. Hooper Mechanisms and Frequency of Resistance to Gatifloxacin in Comparison to AM-1121 and Ciprofloxacin in Staphylococcus aureus Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2755 - 2764. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Honeybourne, D. Banerjee, J. Andrews, and R. Wise Concentrations of gatifloxacin in plasma and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy J. Antimicrob. Chemother., July 1, 2001; 48(1): 63 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Cohn and K. B. Waites Antimicrobial Activities of Gatifloxacin against Nosocomial Isolates of Stenotrophomonas maltophilia Measured by MIC and Time-Kill Studies Antimicrob. Agents Chemother., July 1, 2001; 45(7): 2126 - 2128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Naber, M. Steghafner, M. Kinzig-Schippers, C. Sauber, F. Sörgel, H.-J. Stahlberg, and K. G. Naber Concentrations of Gatifloxacin in Plasma and Urine and Penetration into Prostatic and Seminal Fluid, Ejaculate, and Sperm Cells after Single Oral Administrations of 400 Milligrams to Volunteers Antimicrob. Agents Chemother., January 1, 2001; 45(1): 293 - 297. [Abstract] [Full Text]
|
|